
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics has demonstrated a significant increase in median frataxin (FXN) expression, rising from 2.7 pg/ug at baseline to 13.44 pg/ug at the six-month mark, indicating a favorable response to CTI-1601 treatment. This increase surpasses the >50% expression observed in healthy volunteers, which highlights the potential effectiveness of the company's CPP technology platform. Additionally, the median improvement in the modified Friedreich's Ataxia Rating Scale (mFARS) score of -2.20 points contrasts positively with a decline of +1.00 in the natural history population, further supporting the therapeutic potential of their lead product candidate.
Bears say
Larimar Therapeutics faces significant challenges highlighted by a median change of -2.20 points in the modified Friedreich's Ataxia Rating Scale (mFARS) at one year, which demonstrates worsening patient outcomes compared to the marginal improvement captured in the FACOMS natural history population. Additionally, the company's FY29 revenue estimates have been notably revised down from $659 million to $407 million, indicating growing concerns about its market potential and competitive positioning in the Friedreich’s Ataxia treatment space. This combination of disappointing clinical results and reduced financial outlook contributes to a negative sentiment regarding the stock's future performance.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares